When a long-trusted supplier closes its doors, the immediate question is how to keep research projects on track without introducing new variables. This article offers a practical framework for transitioning peptide work after the Peptide Sciences closure.
Inventory Current Studies and Prioritize
The first step is mapping every active or planned study against its peptide inputs. Studies already underway with existing inventory may not need immediate action. Studies in design or about to begin are the priority — those are where supplier substitution introduces the most risk.
For each peptide, researchers should note the sequence, purity grade, lot number, and any specific COA parameters that informed the original selection. That detail becomes the matching specification when evaluating alternatives.
Long-running studies may also benefit from securing a final reserve of the original lot if any remains available, simply to maintain consistency through completion.
Matching Product Specifications Across Suppliers
Two peptides from two suppliers can share the same name and sequence but differ in purity, counterion, net peptide content, and salt form. Each of those differences can influence experimental results, especially in dose-response work.
Researchers should request full COAs from candidate suppliers and compare them side by side with the original Peptide Sciences COA. Pay particular attention to HPLC purity method, mass spec confirmation, and net peptide content — these are the parameters most likely to vary.
If a candidate supplier cannot provide a comparable COA, that itself is useful information. It suggests the new vendor may not be operating at equivalent quality standards.
Bridging Studies and Validation
For sensitive work, a small bridging study is often worth the time. The idea is to run the same assay or model with both the old and new lot of peptide and confirm comparable activity. This protects published results from being later attributed to a silent supplier change.
Bridging studies also reveal lot-to-lot variability that may exist within the new supplier's production. That information is useful when planning resupply intervals and lot reservations going forward.
Documentation of the bridging study should be included in the lab notebook so that anyone reviewing the work later has a clear record of when and why the supplier transition occurred.
Ensuring Continuity Going Forward
The Peptide Sciences closure is a useful prompt to reduce single-supplier risk in general. Qualifying two or more suppliers per peptide of interest is now common practice. It costs more in upfront validation work but provides resilience against future supply disruptions.
Independent third-party COAs and clear lot traceability matter more than ever during a transition, since they provide the objective comparison points that minimize guesswork.
The research community continues to adapt to supplier shifts, and best practices for peptide procurement transitions are still being refined. All compounds discussed are intended strictly for research use only and are not for human consumption.